Sign In
Buy ALKS
$42.76
+1.44 (+3.48%)
At Close: Jun 03, 2026
Roche (RHHBY) Influenza Drug Gets FDA Nod for Children
02:33pm, Friday, 12'th Aug 2022 Zacks Investment Research
Roche (RHHBY) obtains FDA approval for expanded indication of influenza drug Xofluza.
Alkermes (ALKS) Could Find Support Soon, Here's Why You Should Buy the Stock Now
01:55pm, Thursday, 11'th Aug 2022 Zacks Investment Research
Alkermes (ALKS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall
Cardinal Health (CAH) Q4 Earnings Lag Estimates, Revenues Top
01:45pm, Thursday, 11'th Aug 2022 Zacks Investment Research
Cardinal Health's (CAH) fiscal fourth-quarter results benefit from a solid performance in the Pharmaceutical segment.
Allogene (ALLO) Q1 Earnings Beat, Pipeline Progressing Well
06:54pm, Wednesday, 10'th Aug 2022 Zacks Investment Research
Allogene's (ALLO) second-quarter earnings beat estimates. ALLO is on track to initiate a pivotal phase II study on ALLO-501A in large B cell lymphoma in the coming weeks.
Bausch (BHC) Q2 Earnings & Sales Miss, View Cut, Stock Down
03:56pm, Wednesday, 10'th Aug 2022 Zacks Investment Research
Bausch (BHC) Q2 earnings and sales miss in the second quarter. The company cuts its annual guidance due to the uncertainties in the overall operating environment.
3 Companies Growing Revenue Fast
02:23pm, Wednesday, 10'th Aug 2022
S&P 500 stocks have posted average growth of 6.54% in annual total revenue from 2017 to 2021. The benchmark index for the U.S. stock market closed at 4,122.47 on Tuesday, up nearly 70% over the past f
CONMED (CNMD) Acquires Soft Tissue Implant Start-Up Biorez
01:39pm, Wednesday, 10'th Aug 2022 Zacks Investment Research
CONMED (CNMD) acquires privately-held Biorez, Inc. for $85 million. The deal is set to boost CONMED's sports medicine portfolio with the addition of Biorez's proprietary BioBrace Implant technology.
Perrigo's (PRGO) Q2 Earnings Misses by a Cent, Sales Beat
04:14pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Perrigo (PRGO) delivers mixed second-quarter 2022 results. Higher demand for cough/cold products continues during the reported quarter. Unfavorable currency movements hurt sales and earnings.
Karuna (KRTX) Lags on Q2 Earnings, Up 71% on Schizophrenia Data
04:03pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Though Karuna's (KRTX) earnings miss estimates, KRTX's lead candidate meets late-stage study goals as a potential treatment for adults with schizophrenia.
Shockwave Medical (SWAV) Beats on Q2 Earnings & Revenues
01:31pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Shockwave Medical's (SWAV) second-quarter results reflect robust revenue growth and expansion in gross margin.
Zimmer Biomet (ZBH) Sees Business Recovery, Global Growth
01:29pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Zimmer Biomet (ZBH) revenues ride on continued execution along with strong COVID recovery across most markets.
Alkermes plc (ALKS) CEO Richard Pops on Q2 2022 Results - Earnings Call Transcript
01:14pm, Wednesday, 27'th Jul 2022
Alkermes plc. (NASDAQ:ALKS ) Q2 2022 Earnings Conference Call July 27, 2022 8:00 AM ET Company Participants Sandra Coombs - SVP, IR & Corporate Affairs Iain Brown - CFO Todd Nichols - CCO Richard Pops
Drug, Biotech Stocks' Q2 Earnings on Jul 27: BMY, GSK & More
12:25pm, Tuesday, 26'th Jul 2022
Let's look what is in store for the four drug, biotech companies slated to release quarterly results tomorrow- BMY, GSK, ALKS, TEVA
Bristol-Myers (BMY) to Post Q2 Earnings: What is in the Cards?
04:41pm, Monday, 25'th Jul 2022 Zacks Investment Research
Investors will likely focus on the demand for Eliquis and Opdivo along with incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q2 results. Operating expenses might have jumped.
Is a Beat in Store for Alkermes (ALKS) This Earnings Season?
04:25pm, Monday, 25'th Jul 2022 Zacks Investment Research
Alkermes' (ALKS) second-quarter 2022 results set to report earnings and revenues figures and provide updates on its portfolio of marketed drugs.
